Teva reported success for its experimental anti-celiac antibody in a gluten challenge study, saying the therapy significantly reduced gluten-induced intestinal damage compared with placebo over eight weeks. The company characterized the effect as both statistically significant and clinically meaningful. Teva said the program’s broader potential is supported by earlier vitiligo data involving the same or related pathway approach, and that results are being interpreted in the context of pipeline advancement toward a product-in-a-product profile. Analyses from an ongoing Phase 2a study are underway, and Teva indicated it will present additional data at future scientific meetings. The readout intensifies competition for the first disease-modifying drugs in celiac disease, a market where mechanism-based options have historically faced regulatory and commercial hurdles tied to endpoints and durability.